EV Biologics (EV Biologics) Total Assets : $58.95 Mil (As of Dec. 2017)

View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Total Assets?

EV Biologics's Total Assets for the quarter that ended in Dec. 2017 was $58.95 Mil.

Total Assets is connected with ROA %. EV Biologics's annualized ROA % for the quarter that ended in Dec. 2017 was -19.42%. Total Assets is also linked to Revenue through Asset Turnover. EV Biologics's Asset Turnover for the quarter that ended in Dec. 2017 was 0.84.

EV Biologics Total Assets Historical Data

The historical data trend for EV Biologics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Total Assets Chart

EV Biologics Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Total Assets

57.08

69.56

77.60

36.44

33.28

EV Biologics Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17	Dec17
Total Assets	Get a 7-Day Free Trial												36.44	36.10	33.94	33.28	58.95

EV Biologics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

EV Biologics's Total Assets for the fiscal year that ended in Jun. 2017 is calculated as

Total Assets	=	Total Equity (A: Jun. 2017 )	+	Total Liabilities (A: Jun. 2017 )
	=	3.719	+	29.559
	=	33.28

EV Biologics's Total Assets for the quarter that ended in Dec. 2017 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2017 )	+	Total Liabilities (Q: Dec. 2017 )
	=	42.234	+	16.719
	=	58.95

EV Biologics (OTCPK:YECO) Total Assets Explanation

Total Assets is connected with ROA %.

EV Biologics's annualized ROA % for the quarter that ended in Dec. 2017 is

ROA %	=	Net Income (Q: Dec. 2017 )	/	( (Total Assets (Q: Jun. 2017 )	+	Total Assets (Q: Dec. 2017 ))	/ count )
	=	-8.956	/	( (33.278	+	58.954)	/ 2 )
	=	-8.956	/	46.116
	=	-19.42 %

Note: The Net Income data used here is four times the quarterly (Dec. 2017) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

EV Biologics's Asset Turnover for the quarter that ended in Dec. 2017 is

	Asset Turnover
=	Revenue (Q: Dec. 2017 )	/	( (Total Assets (Q: Jun. 2017 )	+	Total Assets (Q: Dec. 2017 ))	/ count )
=	38.723	/	( (33.278	+	58.954)	/ 2 )
=	38.723	/	46.116
=	0.84

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

EV Biologics Total Assets Related Terms

Thank you for viewing the detailed overview of EV Biologics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

EV Biologics (EV Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Total Assets

Comparable Companies

XCNQ:NIRV ENVB BLCM NLSP BRTX ADTX XKRX:066830 ALLR XMAD:ADL ARTL

Traded in Other Exchanges

N/A

Address

1621 Central Avenue, Cheyenne, WY, USA, 82001

Website

https://www.evbiologics.com

EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.

Executives

Daniel S Mckinney	director, 10 percent owner, officer: CEO	TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan	director	C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3